PD Dr. med. Bernd Metzner

Leitender Arzt für Hochdosistherapie und autologe Stammzelltransplantation

Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie

LIST OF PUBLICATIONS

1) Treatment of Aplastic Anemia with Antilymphocyte-Serum (ALS).
B. Metzner, M. Freund et al. Blut (1985) 51:178

2) Thymic Hyperplasia Following Antineoplastic Chemotherapy in Adult Cancer Patients.
B. Metzner, P. Hendrickx et al. J Cancer Res Clin Oncol (1986) 111(Suppl):S114

3) Treatment of Adult Patients with Disseminated High-Grade Lymphomas of the B-Type.
B. Metzner, M. Freund et al. Blut (1986) 53:221

4) Late Toxicity in Patients with High-Grade Non-Hodgkin-Lymphoma. B. Metzner, M. Möllers et al. J Cancer Res Clin Oncol (1988) 114:S176

5) Treatment of Adult Patients with Disseminated High-Grade Lymphomas of the B-Type.
B. Metzner, M. Freund et al. Blut (1988) 57:197

6) Risiko-adaptierte Therapie hochmaligner Non-Hodgkin Lymphome mit COP-BLAM/IMVP-16: Eine prospektive multizentrische Studie. H.H. Gerhartz, W.Wilmanns, G. Brittinger, M. Engelhard, R. Heinz, D. Huhn, P. Meusers, W. Siegert, A. Stacher, E. Thiel, H. Dietzfelbinger, B. Doerken, W. Dornoff, W. Enne, R. Fuchs,
J. Heise, W. Hettchen, K. Kabelitz, R. Kuse, E. Lengfelder, H. Löffler, B. Metzner, L. Nowicki, H. Radtke, M Schaefers, E. Schumacher, H. Seibt, H.J. Staiger, T. Wagner, M.G. Willems, K.H. Zurborn, T. Zwingers, A.C. Feller, C. v. Schilling, H. Stein, K. Lennert.
Onkologie (1989) 12:22-26

7) Sprechen Knochenmetastasen auf eine Immuntherapie mit Interleukin-2 und Interferon-alpha-2b beim Nierenzellkarzinom an? B. Metzner, R. Siegmund, H. Kirchner, J. Atzpodien, H.J. Illiger. Tumordiagn Ther (1991) 12:192-196

8) Cisplatin/ etoposide/ ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. A. Harstrick, H.-J. Schmoll, C. Bokemeyer, B. Metzner, H.-J. Illiger, W. Berdel, H. Ostermann, C. Manegold, U. Räth, W. Siegert, R. Sonntag, R. Hartenstein, C. Clemm, H. Wilke, H. Poliwoda. J Cancer Res Clin Oncol (1991) 117 (Suppl IV): 198-202

9) Dose escalation of cisplatin, etoposide and ifosfamide with GM-CSF for advanced germ cell tumors. H.-J. Schmoll, C. Bokemeyer, A.Harstrick, H.J. Illiger, B. Metzner, U. Rüther, H. Ostermann, J. Preiss, H. Wilke, J. Hohnloser, et al. Pathol Biol Paris (1992) 39:961

10) A Phase I/II Study of a Stepwise Dose-escalated Regimen of Cisplatin, Etoposide and Ifosfamide plus Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) in Patients with Advanced Germ Cell Tumours. C. Bokemeyer, H.-J. Schmoll, A. Harstrick, H.J. Illiger, B. Metzner, U. Räth, J. Hohnloser, C. Clemm, W. Berdel, W. Siegert, U. Rüther, H. Ostermann, M. Kneba, J.H. Hartlapp, M. Schröder, H. Poliwoda.
Eur J Cancer (1993) 29A:2225-2231

11) Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide and ifosfamide in patients with advanced testicular cancer. C. Bokemeyer, H.-J. Schmoll, B. Metzner, J. Beyer, H.J. Illiger, M. Kneba, H. Ostermann, B. Kynast, U. Rath, H. Poliwoda. Ann Hematol (1993) 67:75-79

12) The Role of Granulocyte-Macrophage Colony-Stimulating Factor in the Treatment of Germ Cell Tumors. C. Bokemeyer, A. Harstrick, U. Rüther, B. Metzner, H.J. Illiger, C. Clemm, W. Siegert, H. Link, H. Ostermann, H.-J. Schmoll. Seminars Oncology (1994) 21 (Suppl 16):57-63

13) Zytostatika. B. Metzner, H.J. Illiger. in: Hämatologie für Praxis und Klinik (Hrsg. R. Kuse) Gustav Fischer Verlag Stuttgart Jena New York (1995) : 265-274

14) Palliative und supportive Therapie. B. Metzner, H.J. Illiger. in: Hämatologie für Praxis und Klinik (Hrsg. R. Kuse) Gustav Fischer Verlag Stuttgart Jena New York (1995) : 315-317

15) Multiinstitutional Home-Therapy Trial of Recombinant Human Interleukin-2 and Interferon Alfa-2 in Progressive Metastatic Renal Cell Carcinoma. J. Atzpodien, E.L. Hänninen, H. Kirchner, H. Bodenstein, M. Pfreundschuh, U. Rebmann, B. Metzner, H.J. Illiger, G. Jakse, T. Niesel, H.J. Scholz, S. Wilhelm, T. Pielmeier, G. Zakrzewski, G. Blum, J. Beier, G.W. Müller, S. Duensing, P. Anton, E. Allhoff, U. Jonas, H. Poliwoda. J Clin Oncology (1995) 13:497-501

16) Phase II Study of Paclitaxel in Patients with Relapsed or Cisplatin-refractory Testicular Cancer. C. Bokemeyer, J. Beyer, B. Metzner, U. Rüther, A. Harstrick, L. Weißbach, U. Köhrmann, W. Verbeek, H.-J. Schmoll. Ann Oncol (1996) 7:31-34

17) Improved Outcome in Adult B-Cell Acute Lymphoblastic Leukemia. D. Hoelzer, W.D. Ludwig, E. Thiel, W. Gaßmann, H. Löffler, C. Fonatsch, H. Rieder, G. Heil, B. Heinze, R. Arnold, D. Hossfeld, T. Büchner, P. Koch, M. Freund, W. Hiddemann, G. Maschmeyer, A. Heyll, C. Aul, T. Faak, R. Kuse, T.H. Ittel, M. Gramatzki, H. Diedrich, K. Kolbe, H.G. Fuhr, K. Fischer, C. Schadeck-Gressel, A. Weiss, I. Strohscheer, B. Metzner, U. Fabry, N. Gökbuget, B. Völkers, D. Messerer, K. Überla. Blood (1996) 87:495-508

18) High Dose Mitoxantrone with Thiotepa, Cyclophosphamide and Autologous Stem Cell
Rescue for High Risk Stage II and Stage III Breast Cancer. A.R. Zander, W. Krüger, N. Kröger, L. Damon, M. Königmann, W.E. Berdel, F. Gieseking, K. Schäfer-Eckart, V. Möbus, N. Frickhofen, H. Wandt, H.J. Illiger, B. Metzner, K. Kolbe, B. Wörmann, L. Trümper, C. Huber, D.K. Hossfeld, H. Maass, W. Jonat.
Bone Marrow Transplantation (1996) 18, Suppl.1:S24-S25

19) Treatment of Brain Metastases in Patients with Testicular Cancer. C. Bokemeyer,
P. Nowak, A. Haupt, B. Metzner, H. Köhne, J.T. Hartmann, L. Kanz, H.-J. Schmoll.
J Clin Oncol (1997) 15:1449-1454

20) Therapie der B-ALL und lymphoblastischer B-NHL in den multizentrischen ALL-Studien des Erwachsenen. D. Hoelzer, N. Gökbuget, W.D. Ludwig, E. Thiel, W. Gaßmann, H. Löffler, C. Fonatsch, H. Rieder, G. Heil, B. Heinze, R. Arnold, D. Hossfeld, T. Büchner, P. Koch, M. Freund, W. Hiddemann, G. Maschmeyer, A. Heyll, C. Aul, T. Faak, R. Kuse, T.H. Ittel, M. Gramatzki, H. Diedrich, K. Kolbe, H.G. Fuhr, K. Fischer, C. Schadeck-Gressel, A. Weiss, I. Strohscheer, B. Metzner, U. Fabry, B. Völkers, D. Messerer.
In: Maligne Lymphome - Biologie, Klassifikation und Klinik (Hrsg. H.-G. Höffkes, M. Uppenkamp) Springer-Verlag Berlin (1997) : 177-187

21) A Phase I/II Study of Sequential, Dose-Escalated, High Dose Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas. C. Bokemeyer, A. Franzke, J.T. Hartmann, C. Schöber, L. Arseniev, B. Metzner, H. Link, L. Kanz, H.-J. Schmoll. Cancer (1997) 80:1221-1227

22) Detection of Melanoma Cells in Peripheral Blood Stem Cell Harvests of Patients with
Progressive Metastatic Malignant Melanoma. M. Probst-Kepper, A. Schrader, J. Buer, J. Grosse, M. Volkenandt, H.-J. Illiger, B. Metzner, J. Kadar, S. Duensing, B. Hertenstein, A. Ganser, J. Atzpodien. British J. Haematology (1997) 98:488-490

23) The Use of Dose-Intensified Chemotherapy in the Treatment of Metastatic Nonseminomatous Testicular Germ Cell Tumors. C. Bokemeyer, A. Harstrick, J. Beyer,
B. Metzner, U. Rüther, J.T. Hartmann, K. Holstein, H.-G. Derigs, R. de Wit, J. Casper, P. Schöffski, I. Kührer, H.-J. Illiger, B. Kempf, A. Reichle, A. Föller, D.K. Hossfeld, J.T. Fischer, W.E. Berdel, H.H. Gerhartz, H. Kirchner, K.-H. Pflüger, H. Ostermann, L. Kanz, H.-J. Schmoll. Sem. Oncol. (1998) 25, Suppl.4: 24-32

24) First-Line High-Dose Chemotherapy for ‘Poor Risk’ Metastatic Non-Seminomatous Testicular Germ Cell Tumors. C. Bokemeyer, A. Harstrick, J. Beyer,
B. Metzner, U. Rüther, J.T. Hartmann, K. Holstein, H.-G. Derigs, R. de Wit, J. Casper, P. Schöffski, I. Kührer, H.-J. Illiger, B. Kempf, A. Reichle, A. Föller, D.K. Hossfeld, J.T. Fischer, W. Berdel, H. Gerhartz, H. Kirchner, K. Pflüger, H. Ostermann, L. Kanz, H.-J. Schmoll. Onkologie (1998) 21, Suppl.2: 23-25

25) Hochdosistherapie beim metastasierten Mammakarzinom.
Metzner B. InFoOnkologie 1998;1:113.

26) Patientenselektion bei der Hochdosistherapie von Hochrisiko-Mammakarzinomen.
Metzner B. InFoOnkologie 1998;1:185.

27) Hochdosistherapie mit Stammzell-Support als Primärtherapie für Patientinnen mit fortgeschrittenem Ovarialkarzinom.
Metzner B. InFoOnkologie 1998;1:255-256.

28) Infectious Complications After High-Dose Therapy and Autologous Stem Cell Transplantation. B. Metzner, R. Dirks, W. Gebauer et al.
Annals of Hematology (1998) 77, Suppl. 2: S160

29) First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis. C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer,
B. Metzner, J.T. Hartmann, H.-J. Schmoll, L. Einhorn, L. Kanz, C. Nichols.
J. Clin. Oncol. (1999) 17: 3450-3456

30) Early Infectious Complications after High-Dose Therapy and Autologous Blood Stem Cell Transplantation. B. Metzner, R. Dirks, W. Gebauer, D. Reschke, T.H. Müller, E. Ost, D. Reichert, B. Rosien, F. del Valle, I. Zirpel, J. Hellkamp, K.P. Kohse, F. Schunter, H.J. Illiger.
Onkologie (1999) 22: 491-496

31) Treatment of Patients With Cisplatin-Refractory Testicular Germ-Cell Cancer. German Testicular Cancer Study Group (GTCSG). C. Bokemeyer, C. Kollmannsberger, A. Harstrick, J. Beyer, A. Gerl, J. Casper, B. Metzner, J.T. Hartmann, H.J. Schmoll, L. Kanz.
Int. J. Cancer (1999) 83: 848-851

32) Hochdosischemotherapie mit Stammzelltransplantation: effektives Therapieregime mit aggressivem Mantelzellymphom.
Metzner B, Illiger HJ. InFoOnkologie 1999;2:258-259.

33) ASHAP - an Effective Salvage Therapy for Recurrent and Refractory Malignant Lymphomas. M. Hänel, N. Kröger, M.M. Hoffknecht, S.O. Peters, B. Metzner, F. Fiedler, D. Braumann, J.C. Schubert, H.J. Illiger, A. Hänel, W.H. Krüger, W. Zeller, H.J. Weh, D.K. Hossfeld, A.R. Zander Ann. Hematol. (2000) 79: 304-311

34) Optimal CD34(+) Cell Dose in Autologous Peripheral-Blood Stem-Cell Transplantation. O. Sezer, K. Possinger, B. Metzner, H.J. Illiger, M. Wattad, W. Heit, H. Fuss, W. Schultze.
J. Clin. Oncol. (2000) 18: 3319-3320

35) Dose-Dependent Effect of Etoposide in Combination with Busulfan Plus Cyclophosphamide as Conditioning for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. N. Kröger, T. Zabelina, S. Sonnenberg, W. Krüger, H. Renges, N. Stute, F. Finkenstein, U. Mayer, K. Holstein, W. Fiedler, H. Colberg, R. Sonnen, R. Kuse, D. Braumann, B. Metzner, F. del Valle, R. Erttmann, H. Kabisch, A.R. Zander
Bone Marrow Transplantation (2000) 26: 711-716

36) Determination of Cytokeratin-Expressing Cells in Blood, Bone Marrow and Blood Progenitor Cell Products. W. Gebauer, E. Fallgren-Gebauer, I. Barklage, B. Metzner, F. Schunter. In: Proceedings of the Forth International Stem Cell Workshop: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells (Editor: W. Schultze) Blackwell Verlag Berlin – Vienna (2000): 98-100

37) M. Hodgkin ohne Ansprechen auf primäre Chemotherapie: Ergebnisse der Hochdosistherapie mit autologer Stammzelltransplantation.
Metzner B. InFoOnkologie 2000;3:36-37.

38) Rezidivtherapie nach Hochdosischemotherapie bei Keimzelltumoren.
Metzner B. InFoOnkologie 2000;3:277-278.

39) Salvage Treatment With Paclitaxel, Ifosfamide and Cisplatin Plus High-Dose Carboplatin, Etoposide and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer. O. Rick, C. Bokemeyer, J. Beyer, J.T. Hartmann, N. Schwella, D. Kingreen, S. Neureither, B. Metzner, J. Casper, H. Wandt, F. Hartmann, H.J. Schmoll, G. Derigs, A. Gerl, W.E. Berdel, L. Kanz, W. Siegert
J. Clin. Oncol. (2001) 19: 81-88

40) Clinical Impact of Germ Cell Tumor Cells in Apheresis Products of Patients Receiving High-Dose Chemotherapy. C. Bokemeyer, A.J. Gillis, K. Pompe, F. Mayer, B. Metzner, N. Schleucher, J. Schleicher, G. Pflugrad-Jauch, JW Oosterhuis, L. Kanz, L.H. Looijenga
J. Clin. Oncol. (2001) 19: 3029-3036

41) IL-2 in Combination with IFN-α and 5-FU versus Tamoxifen in Metastatic Renal Cell Carcinoma: Long-term Results of a Controlled Randomized Clinical Trial. J. Atzpodien, H. Kirchner H.J. Illiger, B. Metzner, D. Ukena, H. Schott, P.J. Funke, M. Gramatzki, S. von Jürgenson, T. Wandert, T. Patzelt, M. Reitz, DGCIN (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group) Brit. J. Cancer (2001) 85: 1130-1136

42) Hochdosischemotherapie mit autologer Stammzelltransplantation für fortgeschrittene Weichteilsarkome bei Erwachsenen.
Metzner B. InFoOnkologie 2001;4:141.

43) Hochdosistherapie mit autologer Knochenmarktransplantation bei follikulären Lymphomen in erster Remission.
Metzner B. InFoOnkologie 2001;4:284-285.

44) Late infectious complications after high dose therapy and autologous stem cell transplantation. B. Metzner, R. Grüneisl, W. Gebauer et al.
Onkologie (2001) 24, Sonderheft 6: Abstr. 522

45) Busulfan, Cyclophosphamide, and Etoposide as high-dose conditioning regimen in patients with malignant lymphoma. M. Hänel, N. Kröger, S. Sonnenberg, M. Bornhäuser, W. Krüger, F. Kroschinsky, A. Hänel, B. Metzner, J. Birkmann, B. Schmidt, M.M. Hoffknecht, F. Fiedler, G. Ehninger, A.R. Zander Ann. Hematol. (2002) 81: 96-102

46) Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. C. Bokemeyer, K. Oechsle, J.T. Hartmann, P. Schöffski, N. Schleucher, B. Metzner, J. Schleicher, L. Kanz
Brit. J. Cancer (2002) 87: 1066-1071

47) Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell-Lymphomen. R. Forstpointner, A. Hänel, R. Repp, S. Hermann, B. Metzner, C. Pott, F. Hartmann, F. Rothmann, H.P.Böck, H. Wandt, M. Unterhalt, W. Hiddemann. Dtsch. Med. Wochenschr. (2002) 127: 2253-2258

48) Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for “Aggressive” Lymphoma. U. Kaiser, I. Uebelacker, U. Abel, J. Birkmann, L. Trümper, H. Schmalenberg, T. Karakas, B. Metzner, D.K. Hossfeld, H.G. Bischoff, A. Franke, M. Reiser, P. Müller, L. Mantovani, M. Grundeis, F. Rothmann, C.-U. v. Seydewitz, R.M. Mesters, E.U. Steinhauer, D. Krahl, K. Schumacher, M. Kneba, M. Baudis, N. Schmitz, R. Pfab, H. Köppler, R. Parwaresch, M. Pfreundschuh, K. Havemann.
J. Clin. Oncol. (2002) 20: 4413-4419

49) Späte infektiöse Komplikationen nach Hochdosistherapie und autologer Blutstammzelltransplantation. B. Metzner, R. Grüneisl, W. Gebauer, D. Reschke, E. Ost, T.H. Müller, D. Reichert, B. Rosien, F. del Valle, I. Zirpel, K.P. Kohse, F. Schunter, H.-J. Illiger.
Med. Klin. (2002) 97: 650-658

50) AL-Amyloidose: Hochdosis-Melphalan mit autologer Stammzelltransplantation.
Metzner B. InFoOnkologie 2002;5:161-162.

51) Analysis of Salvage Treatments for Germ Cell Cancer Patients Who Have Relapsed After Primary High-Dose Chemotherapy Plus Autologous Stem Cell Support. C. Kollmannsberger, N. Schleucher, O. Rick, B. Metzner, J.T. Hartmann, P. Schoffski, J. Beyer, J. Casper, M. Sosada, H.J. Schmoll, I. Bohlke, C. Meisner, L. Kanz, C. Bokemeyer.
Eur J Cancer (2003) 39 : 775-82

52) First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
C. Bokemeyer, N. Schleucher, B. Metzner, M. Thomas, O. Rick, H.-J. Schmoll, C. Kollmannsberger, I. Boehlke, L. Kanz, J.T. Hartmann.
British J. Cancer (2003) 89: 29-35

53) Stem Cell Transplantation in Acute Myeloid Leukemia after Conditioning with Busulfan, Cyclophosphamide and Different Dosages of Etoposide (VP-16). N. Kröger, T. Zabelina, S. Sonnenberg, W. Krüger, H. Renges, N. Stute, F. Finkenstein, U. Mayer, K. Holstein, W. Fiedler, H. Colberg, R. Sonnen, R. Kuse, D. Braumann, B. Metzner, F. del Valle, R. Erttmann, H. Kabisch, A.R. Zander. In: Transplantation in Hematology and Oncology II. (Hrsg.: W.E. Berdel, H. Jürgens, Th. Büchner, J. Ritter, J. Kienast, J. Vormooor) Springer-Verlag Berlin (2003): 219-227

54) Recombinant human erythropoietin, epoietin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial. J.P. Glossmann, A. Engert, G. Wassmer, H. Flechtner, Y. Ko, C. Rudolph, B. Metzner, B. Dörken, S. Wiedenmann, V. Diehl, A. Josting. Ann Hematol. (2003) 82: 469-475

55) High-Dose Therapy for Patients With Primary Multifocal and Early Relapsed Ewing´s Tumors: Results of Two Consecutive Regimens Assessing the Role of Total-Body Irradiation. S. Burdach, A. Meyer-Bahlburg, H.J. Laws, R. Haase, B. van Kaik, B. Metzner, A. Wawer, R. Finke, U. Göbel, J. Haerting, H. Pape, H. Gadner, J. Dunst, H. Juergens. J. Clin. Oncol. (2003) 21: 3072-3078

56) A new conditioning regimen involving total marrow irradiation, busulfan and cyclophophamide followed by autologous PBSCT in patients with advanced multiple myeloma. H. Einsele, M. Bamberg, W. Budach, H. Schmidberger, C.F. Hess, B. Wörmann, C. Meisner, C. Straka, H. Hebart, L. Trümper, N. Kröger, A.R. Zander, S. Hegewisch-Becker, D.K. Hossfeld, H. Schmidt, P. Müller, G. Schlimok, B. Hertenstein, D. Peest, B. Metzner, N. Frickhofen, L. Kanz, W.I. Bensinger. Bone Marrow Transplantation (2003) 32: 593-599

57) Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group. H.-J. Schmoll, C. Kollmannsberger, B. Metzner, J.T. Hartmann, N. Schleucher, P. Schöffski, J. Schleicher, O. Rick, J. Beyer, D. Hossfeld, L. Kanz, W.E. Berdel, R. Andreesen, C. Bokemeyer. J. Clin. Oncol. (2003) 21: 4083-4091

58) Therapeutische Rolle von CAMPATH-1H bei CLL nach Versagen von Fludarabin.
Metzner B. InFoOnkologie 2003;6: .

59) Syngene hämatopoetische Stammzelltransplantation bei Non-Hodgkin-Lymphomen: Vergleich mit allogener und autologer Transplantation.
Metzner B. InFoOnkologie 2003;6:1-2.

60) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. C. Kollmannsberger, J. Beyer, R. Liersch, P. Schöffski, B. Metzner, J.T. Hartmann, O. Rick, K. Stengele, K. Hohloch, C. Spott, L. Kanz, C. Bokemeyer.
J. Clin. Oncol. (2004) 22: 108-114

61) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004 Apr 1;22(7):1188-94.

62) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M; German High-Grade Non-Hodgkins Lymphoma Study Group.
Blood. 2004 Aug 1;104(3):626-33.

63) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.
Zander AR, Kroger N, Schmoor C, Kruger W, Mobus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH, Janicke F, Schumacher M, Jonat W.
J Clin Oncol. 2004 Jun 15;22(12):2273-83.

64) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.
Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M, Hess G, Truemper L, Diehl V, Kropff M, Kneba M, Schmitz N, Metzner B, Pfirrmann M, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov 1;104(9):2667-74.

65) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, Pott C, Hartmann F, Rothmann F, Rohrberg R, Bock HP, Wandt H, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov 15;104(10):3064-71.

66) Langzeit-Beobachtung nach Hochdosis-Chemotherapie und autologer Stammzelltransplantation für hochmaligne B-Zell-Lymphome: verbesserte Ergebnisse für Hochrisiko-Patienten.
Metzner B. InFoOnkologie 2004;7:

67) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W.
Blood. 2005 Apr 1;105(7):2677-84.

68) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber M, Kirchner HH, Dorken B, Hossfeld DK, Kisro J, Metzner B, Berdel WE, Diehl V, Engert A.
Ann Oncol. 2005 Jan;16(1):116-23.

69) Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann JT, Bokemeyer C.
J Cancer Res Clin Oncol. 2005 Apr;131(4):255-60.

70) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W.
J Clin Oncol. 2005 Mar 20;23(9):1984-92.

71) High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkins lymphoma: results of a multicenter phase II study.
Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dorken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A.
Ann Oncol. 2005 Aug;16(8):1359-65.

72) Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the german low grade lymphoma study group (GLSG).
Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M.
Blood. 2005 Aug 25; [Epub ahead of print]

73) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schutt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rosel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group.
Lancet. 2005 Dec 3;366(9501):1935-44. Erratum in: Lancet. 2006 Mar 4;367(9512):730.

74) Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B; German High-Grade Non Hodgkins Lymphoma Study Group (DSHNHL).
Cancer. 2006 Jan 1;106(1):136-45.

75) Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects.
Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander AR, Schulz-Kindermann F, Koch U.
Ann Oncol. 2006 Mar;17(3):415-23. Epub 2005 Dec 15.

76) Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J, Kirchner H, Rebmann U, Soder M, Gertenbach U, Siebels M, Roigas J, Raschke R, Salm S, Schwindl B, Muller SC, Hauser S, Leiber C, Huland E, Heinzer H, Siemer S, Metzner B, Heynemann H, Fornara P, Reitz M.
Br J Cancer. 2006 Aug 21;95(4):463-9. Epub 2006 Aug 8.

77) Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
Kroger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hanel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U.
J Clin Oncol. 2006 Aug 20;24(24):3919-26.

78) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H, Pott C, Seymour JF, Metzner B, Hanel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W; German Low Grade Lymphoma Study Group (GLSG).
Blood. 2006 Dec 15;108(13):4003-8. Epub 2006 Aug 31.

79) Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group.
J Clin Oncol. 2007 Jul 1;25(19):2778-84.

80) Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kroger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom,.
Br J Haematol. 2007 Aug;138(3):330-7.

81) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network.
Blood. 2008 Jan 15;111(2):558-65. Epub 2007 Oct 25. Erratum in: Blood. 2008 Jun 15;111(12):5761.
82) Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group.
J Clin Oncol. 2007 Dec 20;25(36):5742-7.
83) Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.
Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.
Ann Oncol. 2008 May;19(5):861-70. Epub 2008 Jan 3.
84) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, Finke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N; Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
J Clin Oncol. 2008 Jan 10;26(2):218-24.
85) Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkins lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M; German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL).
Ann Oncol. 2008 Mar;19(3):538-44. Epub 2008 Jan 22.
86) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Lancet Oncol. 2008 Feb;9(2):105-16. Epub 2008 Jan 15.
87) Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W.
Ann Oncol. 2008 Jun;19(6):1082-9. Epub 2008 Feb 27.
88) The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W; German Low-Grade Lymphoma Study Group.
Leukemia. 2009 Jan;23(1):153-61. Epub 2008 Sep 25.
89) Improvement of overall survival in advanced stage mantle cell lymphoma.
Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M.
J Clin Oncol. 2009 Feb 1;27(4):511-8. Epub 2008 Dec 15.
90) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Nickelsen M, Ziepert M, Zeynalova S, Glass B, Metzner B, Leithaeuser M, Mueller-Hermelink HK, Pfreundschuh M, Schmitz N.
Ann Oncol. 2009 Jul 1. [Epub ahead of print]

91) Maligne Lymphome: Empfehlungen zur Diagnostik und Therapie, Teil I und II.
Metzner B, Projektgruppe des Tumorzentrums Weser-Ems, 2009

92)High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
Glass B, Ziepert M, Reiser M, Freund M, Trümper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Ann Oncol. 2010 Nov;21(11):2255-61. Epub 2010 May 5.
93) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M.
Blood. 2010 Nov 4;116(18):3418-25. Epub 2010 Jul 21.
94) Dose intensity of chemotherapy in patients with relapsed Hodgkins lymphoma.
Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A.
J Clin Oncol. 2010 Dec 1;28(34):5074-80. Epub 2010 Oct 25.
95) Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.
Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B.
Blood. 2011 Feb 17;117(7):2121-8. Epub 2010 Dec 16.
96) Long-term remissions in metastatic malignant melanoma following chemotherapy and tamoxifen maintenance. Metzner B, Casper J, Hartung G, Rosien B, Hölzle E, Pelzer P, Köhne CH. Onkologie. 2011;34:208-209. Epub 2011 Mar 18.
97) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M.
Blood. 2012 Apr 5;119(14):3276-84. Epub 2012 Feb 15.
98) Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richters Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, Koza V, Mohty M, Remes K, Russell N, Nagler A, Scholten M, de Witte T, Sureda A, Dreger P.
J Clin Oncol. 2012 Apr 30. [Epub ahead of print]

und ca. 130 weitere Abstracts als Coautor